Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
This surge in GLP-1 drug approvals and international market entries is fueling consumer demand and accelerating the growth of the DTC weight-loss medication market
Human evidence - Phase 3 TRIUMPH-1 (Eli Lilly, May 21, 2026) 2,339 adults with obesity or overweight without diabetes
Among adults ages 65 and over, 8% say they have taken a GLP-1 medication for a chronic condition, while just 1% say they have taken these drugs only to lose weight, which may be a reflection of Medicares lack of coverage for prescription drugs used for weight loss
If youre still having junk food and hyper-processed foods, you might be losing weight, but youre losing nutrition
In 2005, the Food and Drug Administration approved the first-ever GLP-1 agonist, exenatide (Byetta)
US$ 26.49
US$ 20.38
US$ 26.96
US$ 27.18
US$ 23.40
